वार्तालाप: आइए बच्चों और किशोरों को COVID-19 के खिलाफ टीकाकरण बंद कर दें। वयस्कों को प्राथमिकता देना फिलहाल हमारा सबसे अच्छा प्रयास है
Some countries who have successfully vaccinated a high proportion of their adult population are now shifting the focus of their COVID-19 vaccine rollout towards children and adolescents.
The following article reviews various international vaccine strategies for the younger population, and explores COVID-19 vaccine safety, including expected vaccine side effects and reports of myocarditis and pericarditis in adolescents. It looks at the potential impact that vaccination of children could have on transmission, herd immunity and keeping schools open.
The World Health Organization (WHO) recognises that globally the vaccine rollout has been slow and inequitable. Low income countries have insufficient vaccine supplies to protect high-priority groups.
In Australia where rates of COVID-19 community transmission is low, it is important that efforts remain on maximising vaccine coverage for adults and those who are at highest risk of severe COVID-19 disease.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
Australia's COVID-19 vaccine coverage update- July 5 2021
The Australian Government Department of Health continue to publish information relating to the COVID-19 vaccine rollout; including data on population coverage.
Latest figures show that 71.64% of Victorians aged 70 years and over have received their first dose of COVID-19 vaccine, with 16% having completed both recommended doses.
To view these statistics and read other information relating to vaccine distribution and uptake, please refer to:
Australian Government Department of Health: Australia's COVID-19 vaccine rollout
The Conversation: Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta
With the most recent COVID-19 outbreaks and lockdowns currently going on across the country, there is pressure to speed up Australia’s COVID-19 vaccine roll out.
It is reported that over six million Australians (30% of those eligible) have received their first dose of a COVID-19 vaccine, with 3.8 million of those receiving their first dose as AstraZeneca. While the benefits of vaccination are well known, there are reports of people cancelling their appointments for dose 2 due to concerns about thrombosis with thrombocytopenia syndrome (TTS).
Current UK data suggests that the risk of developing TTS is far lower following dose 2 AstraZeneca, with a rate of approximately 1 in 1.5 million doses.
Completing a 2 dose course of COVID-19 vaccines is important in order to reach optimal levels of protection. One dose of COVID-19 AstraZeneca offers 33% protection against the Delta strain of the virus currently circulating Sydney. This protection almost doubles to 60% once the second dose has been completed.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
The Conversation: Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
The Therapeutic Goods Administration (TGA) has granted provisional determination to Moderna Australia Pty Ltd for their COVID-19 vaccine candidate, Elasomeran. It is being considered for use in those aged 12 years or older for active immunisation to prevent COVID-19 disease. It is an mRNA vaccine requiring two doses, given 28 days apart.
Granting provisional determination means that Moderna Australia Pty Ltd is now eligible to apply for provisional registration. Following the provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data.
Provisional determination is only granted once the TGA has considered all eligibility criteria, including evidence of a plan to submit comprehensive clinical data.
You can read the press release from the TGA below:
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
For more information on the process of COVID-19 vaccine provisional approval please refer to our reference page:
एमवीईसी: ऑस्ट्रेलिया में सीओवीआईडी-19 वैक्सीन का अनंतिम पंजीकरण
वार्तालाप: ऑस्ट्रेलिया का पहला स्थानीय फाइजर-शैली का COVID वैक्सीन क्या है? और यह हमारी बाहों में कब हो सकता है? एक mRNA विशेषज्ञ बताते हैं
मोनाश विश्वविद्यालय की एक शोध टीम ऑस्ट्रेलिया के पहले एमआरएनए वैक्सीन उम्मीदवार को विकसित करने पर काम कर रही है, जिसके पहले चरण के परीक्षण इस साल अक्टूबर या नवंबर में शुरू होने वाले हैं।
यद्यपि विकास के तहत टीका कोरोनोवायरस के विशिष्ट स्पाइक प्रोटीन के उत्पादन को चिंगारी करने के लिए आरएनए नामक एक आनुवंशिक कोड का उपयोग करके फाइजर और मॉडर्न के टीके के समान सिद्धांतों द्वारा काम करता है, लेकिन प्रमुख उल्लेखनीय अंतर हैं।
सबसे पहले, मोनाश एमआरएनए वैक्सीन कोशिकाओं को स्पाइक प्रोटीन, रिसेप्टर बाइंडिंग डोमेन का एक छोटा सा हिस्सा बनाने के लिए निर्देशित करता है। रिसेप्टर बाइंडिंग डोमेन स्पाइक प्रोटीन की नोक है जो कि वह हिस्सा है जो COVID रोग के नए वेरिएंट बनाने के लिए उत्परिवर्तित हो रहा है। स्पाइक प्रोटीन के इस हिस्से को लक्षित करने से वैरिएंट-विशिष्ट प्रतिक्रियाओं की अनुमति मिलती है, जिसके लिए एक मजबूत नैदानिक आवश्यकता है।
दूसरे, मौजूदा टीकों को वायरस के मूल तनाव पर आधारित किया जाता है जो पहले वुहान में पाया गया था, हालांकि, मोनाश एमआरएनए वैक्सीन को तब से बीटा स्ट्रेन के क्रम में बदल दिया गया है - एक तनाव जो पहली बार दक्षिण अफ्रीका में पाया गया था जिसके लिए मूल से टीके बनाए गए थे। वेरिएंट कम प्रभावी हैं।
यह एमआरएनए टीकों के लचीलेपन पर प्रकाश डालता है, जिसमें दृश्यों को बदला जा सकता है और नए वेरिएंट के लिए अनुकूलित किया जा सकता है जो भविष्य में उभर सकते हैं।
टीके को स्थानीय स्तर पर विकसित करने की योजना पर काम चल रहा है, जो कि mRNA वैक्सीन उत्पादन के लिए ऑस्ट्रेलिया की क्षमता और समग्र रूप से नव विकसित ऑस्ट्रेलियाई आरएनए जैव प्रौद्योगिकी क्षेत्र को विकसित करने की दिशा में एक महत्वपूर्ण कदम है।
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
वार्तालाप: ऑस्ट्रेलिया का पहला स्थानीय फाइजर-शैली का COVID वैक्सीन क्या है? और यह हमारी बाहों में कब हो सकता है? एक mRNA विशेषज्ञ बताते हैं
PHN Webinar: Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS)
The PHN will be hosting a webinar for GPs on Wednesday 30 June featuring a panel of expert speakers including MVEC’s A/Prof Nigel Crawford. The topic for the webinar is Primary care identification and management of thrombosis with thrombocytopenia syndrome (TTS) and will cover:
- pathogenesis
- latest incidence rates in age groups
- incidence of different TTS clinical types
- presentation and identification
- GP management guidelines.
Further information and details on registration can be found via the link below:
RACGP: Government announces new vaccine counselling MBS item number
Federal Health Minister Greg Hunt has announced the introduction of a newly-created MBS item in response to rising vaccine hesitancy related to widespread reporting the rare condition, thrombosis with thrombocytopenia syndrome, following receipt of the COVID-19 AstraZeneca vaccine. The new Medicare item, known as the Level B equivalent, will provide patients over 50 with a $38.75 rebate when receiving COVID vaccine counselling from their GP.
The introduction of this scheme will allow more time for GPs to address patient concerns and provide support in making informed decisions seen as crucial to boosting vaccination rates.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
RACGP: Government announces new vaccine counselling MBS item number
ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021
ATAGI has revised the recommendations for COVID-19 vaccination within Australia.
Due to a higher risk and severity of thrombosis with thrombycytopenia syndrome (TTS) related to the use of COVID-19 AstraZeneca, Comirnaty™ is now the preferred COVID-19 vaccine for individuals aged 16-59 years. Due to the risk of severe outcomes related to COVID-19 disease for individuals aged 60 years and over, the benefits of vaccination in preventing disease outweighs the risk of developing TTS.
Individuals aged less than 60 years who have received their first dose of COVID-19 AstraZeneca without any serious adverse events (eg. anaphylaxis or TTS) should continue to receive their second dose.
अधिक जानकारी के लिए कृपया नीचे दिए गए लिंक को देखें:
ATAGI statement on revised recommendations on the use of COVID-19 Vaccine AstraZeneca, 17 June 2021
The New York Times: A Multibillion-Dollar Plan to End Polio, and Soon
The Global Polio Eradication Initiative has announced a $5.1 billion plan to eradicate polio globally by 2026. In August 2021, African countries were declared free of wild polio, leaving Afghanistan and Pakistan as the only remaining countries with endemic disease. Due to inadequate funding and a lack of political commitment, there has previously been limited success in trying to achieve a polio-free world. The coronavirus pandemic has added further challenges, bringing some polio vaccination programs to a halt.
The new initiative is set to focus on two key goals: integrating polio vaccination programs with other health care initiatives and focusing on areas with chronically low immunisation rates. The plan also ensures vaccine supply and outlines a communication strategy to increase vaccine acceptance. In addition to this, a new oral vaccine has been introduced and is thought to minimise the risk of vaccine-induced polio.
A key focus of the polio eradication program will be on immunising hard-to-reach communities, and training older female health workers, who are more successful in persuading caregivers to vaccinate their children. In order to reinstate polio eradication as a priority, even with competing health challenges in these cash poor countries, experts believe that programs designed to crush polio can also be used to help manage COVID-19 and other diseases.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
The New York Times: A Multibillion-Dollar Plan to End Polio, and Soon
ABC: With their AstraZeneca supplies nearing expiration, PNG comes up with creative ways to vaccinate people
There has been a slow uptake of COVID-19 vaccines in Papua New Guinea (PNG), thought to be due to the impact of misinformation. With stocks of AstraZeneca COVID-19 vaccines nearing their expiry date, creative initiatives have been undertaken in an effort to boost uptake.
Among these initiatives is the development of PNG’s first mobile vaccination unit, a yellow bus. The bus takes vaccines to communities enabling the locals to see the vaccination process in action.
All supplies, vaccines and emergency equipment required to vaccinate can be taken to villages in the bus, some of which don't have their own health clinics. This community led initiative enables people to seek information from health providers in an effort to overcome hesitancy and misinformation and get vaccinated.
With widespread community transmission, a focus remains on encouraging health care workers to get vaccinated, as well as eligible members of the community such as the elderly and those with comorbidities.
To read more about Papua New Guinea’s COVID-19 vaccine rollout and the mobile vaccination unit please refer to the link below: